Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of so...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

55 Cambridge Parkway, Suite 6W, Cambridge, United States

focafoca99 Jul. 3 at 5:06 PM

$AMLX is the subject of a shareholder rights investigation by a law firm.

0 · Reply

LoveRetailFroth Jul. 2 at 1:48 PM

$TEM Good Morning my bio 💎 s☕️ Lots of Buyout here! 10X $AMLX $SANA $RXRX

0 · Reply

LoveRetailFroth Jul. 1 at 3:58 PM

$AMLX Oh all the shenanigans 😂 $60 plus 🚀

0 · Reply

LoveRetailFroth Jun. 30 at 3:29 PM

$AMLX Good Morning 💎s $RXRX $SANA $ARBE

0 · Reply

LoveRetailFroth Jun. 29 at 10:02 PM

$AMLX hit 52 week high today. Will hit ATH on Avexitide data in Q3 🍺 $40

0 · Reply

LoveRetailFroth Jun. 29 at 1:04 PM

$RXRX Good Morning ☕️ Notice before 🌋. Multi Baggers. $TEM $AMLX $VIVO GL!

0 · Reply

LoveRetailFroth Jun. 27 at 3:30 PM

$RXRX Good Morning ☕️ I normally don’t post on weekends. But, when things turn, notice before 🌋. Multi Baggers. $TEM $AMLX $VIVO Have a great weekend & GL! Next week could be special.

0 · Reply

ajmore Jun. 27 at 8:28 AM

$AMLX

0 · Reply

LoveRetailFroth Jun. 26 at 2:52 PM

$RXRX It will be slow & sudden 🌋! Feel the tremors🚀 $VIVO $TEM $AMLX

0 · Reply

LoveRetailFroth Jun. 26 at 1:39 PM

$AMLX Remember FDA accepted Resubmission from $REPL AMLX voluntarily withdrew ALS 3 yrs ago. Now back to 40s 🚀

0 · Reply

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-06-25T11:30:42.000Z - 9 days ago

Amylyx price target raised to $40, named a Best Idea at Guggenheim

2026-06-23T12:10:04.000Z - 11 days ago

Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial

Jun 23, 2026, 7:00 AM EDT - 11 days ago

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Jun 10, 2026, 10:40 AM EDT - 24 days ago

Amylyx Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:00 AM EDT - 26 days ago

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Jun 4, 2026, 9:00 AM EDT - 4 weeks ago

Amylyx Pharmaceuticals Transcript: AGM 2026

2026-05-15T17:48:26.000Z - 7 weeks ago

Amylyx announces publication of Phase 2 open-label HELIOS trial data

May 15, 2026, 12:11 PM EDT - 7 weeks ago

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 13, 2026, 4:40 PM EDT - 7 weeks ago

Amylyx Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T16:21:43.000Z - 2 months ago

Amylyx sees cash runway into 2028

May 7, 2026, 8:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 6, 2026, 9:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-05-05T11:36:12.000Z - 2 months ago

Amylyx announces launch of U.S. EAP for adults with PBH

May 5, 2026, 7:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-28T10:58:40.000Z - 2 months ago

Amylyx price target raised to $21 from $19 at Mizuho

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Proxy statement: Proxy filing

Apr 15, 2026, 8:45 AM EDT - 2 months ago

Amylyx Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 9:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-24T11:05:57.000Z - 3 months ago

Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide

Mar 24, 2026, 7:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

2026-03-19T10:50:43.000Z - 3 months ago

Amylyx price target raised to $30 from $25 at Guggenheim

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-04T14:38:10.000Z - 4 months ago

Amylyx price target raised to $34 from $28 at H.C. Wainwright

Mar 3, 2026, 11:10 AM EST - 4 months ago

Amylyx Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T13:12:32.000Z - 4 months ago

Amylyx files automatic mixed securities shelf

Mar 3, 2026, 8:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Earnings release: Q4 2025

2026-03-03T12:37:16.000Z - 4 months ago

Amylyx reports Q4 EPS (30c), consensus (34c)

Mar 3, 2026, 7:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-02T21:11:21.000Z - 4 months ago

Amylyx initiated with a Buy at Stifel

Mar 2, 2026, 6:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Slides: Corporate presentation

Feb 26, 2026, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

2026-02-20T12:26:13.000Z - 4 months ago

Amylyx price target raised to $19 from $15 at BofA

2026-02-19T12:36:40.000Z - 4 months ago

Amylyx price target raised to $19 from $18 at Mizuho

2026-02-19T12:29:43.000Z - 4 months ago

Amylyx price target raised to $19 from $18 at Mizuho

2026-02-10T11:19:36.000Z - 5 months ago

Amylyx price target raised to $28 from $20 at H.C. Wainwright

Jan 29, 2026, 5:05 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

2026-01-08T12:16:47.000Z - 6 months ago

Amylyx selects AMX0318 as development candidate for PBH

Jan 8, 2026, 7:00 AM EST - 6 months ago

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

2025-12-19T14:11:21.000Z - 7 months ago

Amylyx price target lowered to $15 from $16 at BofA

Dec 5, 2025, 9:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 4:00 PM EST - 7 months ago

Amylyx Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:20 AM EST - 7 months ago

Amylyx Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 10, 2025, 4:30 PM EST - 8 months ago

Amylyx Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T12:31:55.000Z - 8 months ago

Amylyx price target raised to $18 from $16 at Mizuho

Nov 6, 2025, 8:00 AM EST - 8 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Amylyx Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Amylyx Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 8 months ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 8 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Sep 12, 2025, 7:30 AM EDT - 10 months ago

Amylyx Pharmaceuticals Slides: Corporate Presentation

Sep 10, 2025, 10:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:06 AM EDT - 10 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 10 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 9, 2025, 3:10 PM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 4:50 PM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 1:00 PM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 27, 2025, 7:28 AM EDT - 11 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 13, 2025, 9:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: Status Update

Jul 13, 2025, 9:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Press release: Status Update

Jul 13, 2025, 9:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Slides: Status Update

Jul 13, 2025, 5:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 1:25 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 2, 2025, 4:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Slides: Investor Presentation

May 21, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 20, 2025, 5:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 4:55 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

focafoca99 Jul. 3 at 5:06 PM

$AMLX is the subject of a shareholder rights investigation by a law firm.

0 · Reply

LoveRetailFroth Jul. 2 at 1:48 PM

$TEM Good Morning my bio 💎 s☕️ Lots of Buyout here! 10X $AMLX $SANA $RXRX

0 · Reply

LoveRetailFroth Jul. 1 at 3:58 PM

$AMLX Oh all the shenanigans 😂 $60 plus 🚀

0 · Reply

LoveRetailFroth Jun. 30 at 3:29 PM

$AMLX Good Morning 💎s $RXRX $SANA $ARBE

0 · Reply

LoveRetailFroth Jun. 29 at 10:02 PM

$AMLX hit 52 week high today. Will hit ATH on Avexitide data in Q3 🍺 $40

0 · Reply

LoveRetailFroth Jun. 29 at 1:04 PM

$RXRX Good Morning ☕️ Notice before 🌋. Multi Baggers. $TEM $AMLX $VIVO GL!

0 · Reply

LoveRetailFroth Jun. 27 at 3:30 PM

$RXRX Good Morning ☕️ I normally don’t post on weekends. But, when things turn, notice before 🌋. Multi Baggers. $TEM $AMLX $VIVO Have a great weekend & GL! Next week could be special.

0 · Reply

ajmore Jun. 27 at 8:28 AM

$AMLX

0 · Reply

LoveRetailFroth Jun. 26 at 2:52 PM

$RXRX It will be slow & sudden 🌋! Feel the tremors🚀 $VIVO $TEM $AMLX

0 · Reply

LoveRetailFroth Jun. 26 at 1:39 PM

$AMLX Remember FDA accepted Resubmission from $REPL AMLX voluntarily withdrew ALS 3 yrs ago. Now back to 40s 🚀

0 · Reply

LoveRetailFroth Jun. 26 at 1:33 PM

$RXRX Yeah believe me you, SQUEEZE here will be EPIC ☕️ $VIVO $SANA $AMLX

0 · Reply

LoveRetailFroth Jun. 25 at 8:53 PM

$AMLX $55? Yeah but higher with the pipeline 🍺

0 · Reply

AC_TRADER Jun. 25 at 8:12 PM

$AMLX great entry was 15.73 :)

1 · Reply

Quantumup Jun. 25 at 6:40 PM

Guggenheim⬆️ $AMLX-$40,⬆️GLP-1R antagonism penetration in severe PBH patients to 70%—market share to 90%—bull case = $55,⬆️to BEST IDEA and reiterated at Buy. $MBX Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2070215249798774800?s=20

0 · Reply

anachartanalyst Jun. 25 at 4:01 PM

$AMLX https://anachart.com/wp-content/uploads/2026/06/1782403299_soc-img.jpg

0 · Reply

ajmore Jun. 25 at 3:24 PM

$AMLX named best idea at Guggenheim. the firm "strongly" believes Lucidity will be positive and pave the way for amylyx to "dominate the 6bln+ US PBH market for years to come", the analyst tells investors. seriously, we could see 60-100 on data.

3 · Reply

LoveRetailFroth Jun. 25 at 2:44 PM

$AMLX $40! 2 yr target $70- $100

0 · Reply

ajmore Jun. 25 at 2:40 PM

$AMLX Guggenheim raises target from 30 usd to 40 usd!

0 · Reply

LoveRetailFroth Jun. 25 at 2:29 PM

$TEM This $100 $AMLX ! ALS! Back to $40 $TEMT

0 · Reply

Madmone Jun. 25 at 2:19 PM

$AMLX How is this company worth anything?

0 · Reply

LoveRetailFroth Jun. 25 at 2:14 PM

$AMLX So you can’t buy this on TOS. You have to call your broker ☕️🚀 $40

0 · Reply

LoveRetailFroth Jun. 25 at 1:34 PM

$RXRX Yeah believe me you, SQUEEZE here will be EPIC ☕️ $VIVO $SANA $AMLX

0 · Reply

Market Cap	2.03B
Revenue (ttm)	0.00
Net Income (ttm)	-144.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,392,700
Avg Vol	1,394,040
Day's Range	N/A - N/A
Shares Out	111.19M
Stochastic %K	74%
Beta	-0.20
Analysts	Strong Sell
Price Target	$24.40